FDA warned Nupack Inc. that its dietary supplements were unapproved drugs and made without required manufacturing-practice records.
What happened
FDA inspected Nupack Inc.'s Elgin, IL facility from August 20, 2025, through September 24, 2025, and reviewed product labels and the website www.unitechusk.com. FDA found the products promoted for treating or preventing diseases, making them unapproved new drugs, and found misbranding and current good manufacturing practice (CGMP) violations for dietary supplements, including missing product specifications, master manufacturing records, batch production records, and returned-product procedures. At the inspection's end FDA issued a Form FDA 483 (inspection observations); the firm responded January 12, 2026, asking for four more weeks, and FDA says it has received no further correspondence.
What FDA found
The website and labels claim Cardiag, Diabetech, Cleanse-CAMP, MACA, Kidney Cleanse, and Pure Pysyllium Husk treat or prevent diseases such as diabetes, heart disease, high blood pressure, constipation, and erectile dysfunction, so FDA treats them as unapproved new drugs.
sections 201(g)(1)(B), 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(g)(1)(B), 321(p), 331(d), 355(a)]Cardiag, Diabetech, and MACA are misbranded because they lack adequate directions for use by a layperson for diseases that require licensed practitioner supervision.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Because Nupack did not establish finished-product specifications for identity, purity, strength, composition, and contamination limits for Cardiag, Cleanse-camp, and MACA 1000 mg, FDA calls the supplements adulterated.
21 CFR 111.70(e); Act section 402(g)(1) [21 U.S.C. 342(g)(1)]Nupack did not prepare a written master manufacturing record for each unique formulation and batch size of Cardiag, Cleanse-camp, and MACA 1000 mg.
21 CFR 111.205(a)Nupack did not prepare a batch production record every time it manufactured a batch of Cardiag, Cleanse-camp, or MACA 1000 mg.
21 CFR 111.255(a)Nupack did not establish written procedures for handling returned dietary supplements, including destroying, salvaging, reprocessing, releasing, or investigating implicated batches.
21 CFR Part 111, Subpart N
What FDA wants
Within 15 working days of receipt, notify FDA in writing of the specific steps taken to address the violations, explain steps to prevent recurrence, and include related documents; if corrective actions cannot be completed in that time, state the reason and when they will be done. If the firm believes its products are not in violation, it should include its reasoning and supporting information.
Who should pay attention
- retailers and brands selling dietary supplements made by Nupack
- other dietary supplement manufacturers
- labeling and regulatory review teams
This is a summary. Read the original letter on fda.gov.